Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial is a research paper published in Blood (2020). On theSindex it has a DataRank of 3.7. It has been cited 95 times, with 79 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.685
From this paper's citation signal
Citation Network Contribution
3.0
From 63 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 79 citers.
NCI NIH HHS
Grant: P30 CA091842
NCI NIH HHS
Grant: U10 CA180850
NCI NIH HHS
Grant: UG1 CA233339
NCI NIH HHS
Grant: U10 CA180833
NCI NIH HHS
Grant: U10 CA180882
CCR NIH HHS
Grant: HHSN261200800001C
NCI NIH HHS
Grant: U10 CA180791
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: UG1 CA189960
NCI NIH HHS
Grant: HHSN261200800001E
NCI NIH HHS
Grant: U10 CA180888
NCI NIH HHS
Grant: UG1 CA233290
FWCI
8.14
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients
Additional file 1 of Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients